232 related articles for article (PubMed ID: 16278010)
1. Comparison of secondary and primary ovarian malignancies reveals differences in their pre- and perioperative characteristics.
Antila R; Jalkanen J; Heikinheimo O
Gynecol Oncol; 2006 Apr; 101(1):97-101. PubMed ID: 16278010
[TBL] [Abstract][Full Text] [Related]
2. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
[TBL] [Abstract][Full Text] [Related]
3. Can we preoperatively risk stratify ovarian masses for malignancy?
Oltmann SC; Garcia N; Barber R; Huang R; Hicks B; Fischer A
J Pediatr Surg; 2010 Jan; 45(1):130-4. PubMed ID: 20105592
[TBL] [Abstract][Full Text] [Related]
4. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
5. Metastatic colorectal adenocarcinoma involving the ovary with elevated serum CA125: a potential diagnostic pitfall.
Lewis MR; Euscher ED; Deavers MT; Silva EG; Malpica A
Gynecol Oncol; 2007 May; 105(2):395-8. PubMed ID: 17335881
[TBL] [Abstract][Full Text] [Related]
6. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.
Young RH
Adv Anat Pathol; 2007 May; 14(3):149-77. PubMed ID: 17452813
[TBL] [Abstract][Full Text] [Related]
7. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
Peters-Engl C; Medl M; Ogris E; Leodolter S
Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
[TBL] [Abstract][Full Text] [Related]
8. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
9. Preoperative predictors for residual tumor after surgery in patients with ovarian carcinoma.
de Jong D; Eijkemans MJ; Lie Fong S; Gerestein CG; Kooi GS; Baalbergen A; van der Burg ME; Burger CW; Ansink AC
Oncology; 2007; 72(5-6):293-301. PubMed ID: 18198490
[TBL] [Abstract][Full Text] [Related]
10. Women with undiagnosed colorectal adenocarcinomas presenting with ovarian metastases: clinicopathologic features and comparison with women having known colorectal adenocarcinomas and ovarian involvement.
Judson K; McCormick C; Vang R; Yemelyanova AV; Wu LS; Bristow RE; Ronnett BM
Int J Gynecol Pathol; 2008 Apr; 27(2):182-90. PubMed ID: 18317225
[TBL] [Abstract][Full Text] [Related]
11. Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study.
Burger RA; Darcy KM; DiSaia PJ; Monk BJ; Grosen EA; Gatanaga T; Granger GA; Wang J; Tian C; Hanjani P; Cohn DE
Cancer; 2004 Jul; 101(1):106-15. PubMed ID: 15221995
[TBL] [Abstract][Full Text] [Related]
12. Patients with a history of epithelial ovarian cancer presenting with a breast and/or axillary mass.
Karam AK; Stempel M; Barakat RR; Morrow M; Gemignani ML
Gynecol Oncol; 2009 Mar; 112(3):490-5. PubMed ID: 19101713
[TBL] [Abstract][Full Text] [Related]
13. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study.
Topalak O; Saygili U; Soyturk M; Karaca N; Batur Y; Uslu T; Erten O
Gynecol Oncol; 2002 Apr; 85(1):108-13. PubMed ID: 11925128
[TBL] [Abstract][Full Text] [Related]
14. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
[TBL] [Abstract][Full Text] [Related]
15. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
[TBL] [Abstract][Full Text] [Related]
16. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
17. Relapse and survival in early-stage ovarian cancer.
Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
[TBL] [Abstract][Full Text] [Related]
18. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
19. Preoperative clinical and radiological features of metastatic ovarian tumors.
Bruchim I; Ben-Harim Z; Piura E; Tepper R; Fishman A
Arch Gynecol Obstet; 2013 Sep; 288(3):615-9. PubMed ID: 23471547
[TBL] [Abstract][Full Text] [Related]
20. Role of appendectomy at the time of primary surgery in patients with early-stage ovarian cancer.
Ramirez PT; Slomovitz BM; McQuinn L; Levenback C; Coleman RL
Gynecol Oncol; 2006 Dec; 103(3):888-90. PubMed ID: 16806436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
